Ask HopeStage to review this study with me
Study ID: NCT01364662. We help you review the study, but cannot decide medical eligibility.
CompletedNCT01364662
SPN-810 for ADHD
This study is completed in the United States. It is testing SPN-810 for ADHD.
ADHDDrugFrom 6 Years to 12 Years
Key information made simple
This summary needs review. Please check the official study record and contact the research team for details.
Your next step
The official record suggests in-person participation through a research setting. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually matching the main diagnosis and meeting the main study requirements. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateJune 2011
- Recruitment status
- Completed
- Estimated enrollment
- Not clearly listed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT01364662
- Official title
- A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT01364662. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in United States.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Who might this study be for?
This study may concern people with adhd; age range: From 6 Years to 12 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Supernus Pharmaceuticals, Inc., which appears to be a pharmaceutical company. Sponsor website: https://www.supernus.com. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT02059642
MG01CI 1400 mg Compared With Placebo for ADHD
This study is completed in the United States and in Israel. It is testing MG01CI 1400 mg Compared With Placebo for ADHD.
CompletedNCT00500149
Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) for ADHD
This study is completed in the United States. It is testing time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) for ADHD.
CompletedNCT02555150
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
This study is completed. It focuses on ADHD and currently lists study information in the United States.